About Contact Us Careers

In-Vitro IBD Diagnostic Market Trends

Request Free Sample Copy

Report ID: 3414
Published Date: Oct 18, 2024
Report Format: PDF, PPT

Buy Now

In-Vitro IBD Diagnostic Market Trends

Growth Drivers

Increasing Prevalence of IBD
Rapid Research and Development in Gastro Sciences

Challenges

Stringent Product Approval Process

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	5.3%
Base Year Market Size (2023)	USD 1.83 billion
Forecast Year Market Size (2036)	USD 3.58 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

In-Vitro Inflammatory Bowel Disease Diagnostic Market Size Report 2036

Author Credits: Radhika Pawar

Report ID: 3414
Published Date: Oct 18, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of in-vitro IBD diagnostic is assessed at USD 1.91 billion.

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market size was over USD 1.83 billion in 2023 and is projected to reach USD 3.58 billion by 2036, growing at around 5.3% CAGR during the forecast period i.e., between 2024-2036.

North America industry is estimated to account for largest revenue share of 44% by 2036

The major players in the market are are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, and others.

Inquiry Before Buying Request Free Sample